Arrhythmic risk in ventricular cardiac tumors: A comparative imaging and clinical analysis Authors: Mohamed S Riad, Mohamed M Abdelfadil, Mostafa Wanees Ahmed El Husseny, Taha Abd-ElSalam Ashraf Taha, Eslam Ahmed, Mahmoud Shaaban, Ayman M Ibrahim, Ahmed Elguindy, Hesham Bahaa, Hatem Hosny, Ahmed Afifi, Omnia Kamel Published: 2026 ABSTRACT AbstractBackgroundVentricular arrhythmias and sudden cardiac death (SCD) are serious complications of cardiac tumors, but predictors of arrhythmic risk in patients with ventricular masses remain poorly defined.ObjectiveTo identify clinical, anatomical, and imaging features associated with ventricular arrhythmia/SCD (VA/SCD) presentation in patients with ventricular cardiac masses.MethodsWe performed a retrospective comparative cohort study using a prospectively maintained registry at Aswan Heart Centre including patients with ventricular cardiac masses (2012–2024). Patients with sustained ventricular tachyarrhythmia, survived sudden cardiac arrest, or arrhythmic death were classified as the VA/SCD group and compared with patients without significant ventricular arrhythmia. Continuous variables were compared using Mann–Whitney U test and categorical variables using Fisher's exact test.ResultsAmong 34 patients, 11 (32.4%) had VA/SCD presentation during a median follow-up of 3 years. The VA/SCD group was older (14 vs. 1 year, p = 0.044) and more frequently presented with syncope (45.5% vs. 0%, p = 0.002) and palpitations (63.6% vs. 21.7%, p = 0.026). Tumors were larger (6.8 vs. 2.3 cm, p < 0.001) and exclusively solitary (100% vs. 60.9%, p = 0.017). Fibromas and vascular tumors were more frequent, whereas rhabdomyomas were confined to the non-arrhythmic group (p = 0.002). Late gadolinium enhancement was numerically higher in the VA/SCD group (90.9% vs. 57.9%, p = 0.100). Ventricular function and hemodynamic parameters were similar between groups.ConclusionsVA/SCD presentation in ventricular cardiac masses is associated with a phenotype of larger size, solitary morphology, and arrhythmogenic histology rather than impaired ventricular function. But these patterns were confounded by tumor type, especially pediatric multifocal rhabdomyomas.Keywords: Cardiac tumors, Ventricular arrhythmia, Magnetic resonance imaging What is new •This study provides comparative analyses specifically exploring predictors of ventricular arrhythmia and sudden cardiac death in patients with ventricular cardiac masses. This study provides comparative analyses specifically exploring predictors of ventricular arrhythmia and sudden cardiac death in patients with ventricular cardiac masses. •Arrhythmic risk was observed in a distinct tumor phenotype characterized by larger size, solitary morphology, and arrhythmogenic histology (particularly fibromas and vascular tumors). Arrhythmic risk was observed in a distinct tumor phenotype characterized by larger size, solitary morphology, and arrhythmogenic histology (particularly fibromas and vascular tumors). •Conventional markers of mechanical severity, including ventricular systolic function, valvular disease, and outflow tract obstruction, did not differentiate higher-risk patients. Conventional markers of mechanical severity, including ventricular systolic function, valvular disease, and outflow tract obstruction, did not differentiate higher-risk patients. •Cardiac magnetic resonance tissue characterization, particularly late gadolinium enhancement, may offer incremental value for identifying arrhythmogenic substrate. Cardiac magnetic resonance tissue characterization, particularly late gadolinium enhancement, may offer incremental value for identifying arrhythmogenic substrate. •These findings support a risk-adapted management strategy incorporating tumor phenotype and multimodality imaging to guide rhythm surveillance and surgical timing. These findings support a risk-adapted management strategy incorporating tumor phenotype and multimodality imaging to guide rhythm surveillance and surgical timing. Introduction Primary cardiac tumors are rare, with an estimated post-mortem incidence of approximately 0.02%, whereas secondary cardiac involvement from metastatic disease is considerably more common. Although most primary cardiac tumors are histologically benign, their clinical consequences may be profound. Cardiac masses can lead to substantial morbidity and mortality through several mechanisms, including intracavitary obstruction, embolization, myocardial dysfunction, and arrhythmogenesis [1], [2]. Among these manifestations, ventricular arrhythmias represent one of the most clinically important and least predictable complications. The arrhythmic spectrum ranges from isolated premature ventricular complexes to sustained ventricular tachycardia (VT), ventricular fibrillation, aborted sudden cardiac arrest, and sudden cardiac death (SCD) [3], [4]. In pediatric primary-tumor series, clinically important arrhythmias have been reported in approximately 20%–30% of patients [5]. The mechanisms underlying these events are heterogeneous and appear to depend on tumor pathology, size, location, and interaction with the surrounding myocardium. Solid intramural tumors such as fibromas may act as fixed anatomical substrates for re-entry, whereas infiltrative or highly vascular lesions may disrupt myocardial architecture, alter conduction, or promote abnormal automaticity [6]. Despite the recognized arrhythmogenic potential of cardiac tumors, the available literature remains dominated by case reports, small case series, and pathology-specific descriptions. Comparative data exploring the factors that predispose certain ventricular masses to malignant arrhythmias are scarce. As a result, there is insufficient evidence to guide early risk stratification at diagnosis or to identify which patients require closer rhythm surveillance and more aggressive intervention. Accordingly, we performed a descriptive comparative analysis within a contemporary single-center registry. The primary objective was to characterize clinical, anatomical, and multimodality imaging patterns accompanying VA/SCD versus non-arrhythmic presentation in patients with ventricular cardiac tumors. A secondary objective was to place these group-level observations in the context of individual tumor types, treatment, and documented outcomes. Methods Study design and population We conducted a retrospective comparative study using data from an institutional registry at Aswan Heart Centre (AHC). The registry included 71 consecutive patients diagnosed with primary or secondary cardiac tumors between December 2012 and February 2024. From this overall registry cohort, the present analysis was restricted to patients with ventricular cardiac masses. Patients were eligible for this analysis if imaging demonstrated a mass involving either ventricle or its adjacent pericardium. Pediatric status was defined as age < 18 years; 24 patients were pediatric and 10 were adults >18 years. Definite diagnosis of tumor type was based on tissue biopsy or imaging and clinical characteristics when biopsy was not available. Group assignment The thirty-four patients with ventricular masses were divided into two groups based on their arrhythmic presentation: Arrythmic group (VA/SCD group): Patients who presented with or developed at least one of the following: •Documented sustained ventricular tachyarrhythmia. Documented sustained ventricular tachyarrhythmia. •Sudden cardiac death defined as unexpected natural death from a cardiac cause within a short time period, generally ≤1 h from the onset of symptoms, with suspected arrhythmic cause. Sudden cardiac death defined as unexpected natural death from a cardiac cause within a short time period, generally ≤1 h from the onset of symptoms, with suspected arrhythmic cause. •Survived sudden cardiac arrest with suspected arrhythmic cause. Survived sudden cardiac arrest with suspected arrhythmic cause. Non-arrhythmic group: Patients without clinically significant ventricular arrhythmia. These two groups were then compared across multiple domains, including demographic characteristics, clinical presentation, tumor pathology, multimodality imaging features, and hemodynamic parameters to identify factors associated with arrhythmic risk. Because tumor type could account for apparent group differences, treatment and outcomes were additionally summarized by tumor category. Data collection Clinical, imaging, and outcome data were collected from electronic and paper medical records. Demographic and clinical variables included age at diagnosis, sex, presence of tuberous sclerosis complex, and presenting symptoms such as palpitations, syncope. Arrhythmia assessment All available 12‑lead electrocardiograms and ambulatory Holter recordings were reviewed. Ventricular arrhythmias were classified according to standard definitions. Sustained VT was defined as VT lasting more than 30 s or requiring termination because of hemodynamic instability. Multimodality imaging assessment All patients underwent transthoracic echocardiographic evaluation, Cardiac magnetic resonance (CMR) served as the principal modality for tissue characterization when available. CMR assessment included tumor morphology, anatomical extent, signal characteristics on T1-weighted and T2-weighted sequences, first-pass perfusion, and late gadolinium enhancement (LGE). Computed tomography studies were reviewed, when performed, for relevant data. Treatment and outcome assessment Management and documented outcomes were reviewed by tumor type. Missing longitudinal rhythm data, treatment outside AHC, and loss to follow-up were retained as limitations rather than interpreted as event-free follow-up. Statistical analysis Statistical analysis was performed to compare patients with VA/SCD and those without clinically significant ventricular arrhythmia. Continuous variables were assessed for distribution and, given the small sample size and non-normal distribution of several variables, were summarized as median and interquartile range (IQR). Categorical variables were summarized as frequency and percentage. Comparisons between the two groups were performed using the Mann–Whitney U test for continuous variables and Fisher's exact test for categorical variables, as appropriate. All tests were two-sided, and a p value <0.05 was considered statistically significant. Because of the limited number of patients and outcome events, the analysis was considered exploratory, and no multivariable regression model was performed to avoid overfitting and unstable estimates. Exact p-values are reported to describe the observed differences and generate hypotheses, rather than to establish independent associations or clinically applicable risk thresholds. Accordingly, the identified variables should be interpreted as factors associated with VA/SCD rather than independent predictors. For imaging variables, analyses were performed using an available-case approach, such that percentages for each imaging characteristic were calculated based on the number of patients with interpretable imaging data for that specific parameter. No imputation was performed for missing data. Ethics statement The study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the local institutional review board and written informed consent for inclusion in the registry and use of anonymized data for research purposes was obtained in accordance with institutional policy. Results Demographics and clinical characteristics A total of 34 patients with ventricular cardiac masses were included in this analysis, of whom 11 had significant ventricular arrhythmia (8) or sudden cardiac death (3). Comparison of baseline demographic and clinical characteristics is summarized in Table 1. Table 1Demographics and Clinical Characteristics Stratified by Arrhythmic Presentation.VariableVA\ SCD Group (n = 11)Non-Arrhythmic Group (n = 23)P-ValueAge (years), Median [IQR]14 (1.13–31.50)1 (0.25–14.50)0.044Pediatric Patient (<18y), n (%)6 (54.5)18 (78.3)0.232Male Sex, n (%)5 (45.5)15 (65.2)0.458Tuberous Sclerosis, n (%)0 (0)10 (43.5)0.014Clinical Presentation Syncope, n (%)5 (45.5)0 (0)0.002 Palpitations, n (%)7 (63.6)5 (21.7)0.026Data are presented as n (%) for categorical variables and Median [Interquartile Range] for continuous variables. Valid percent was used. P-value <0.05 indicates statistical significance. P-values were calculated using Fisher's Exact Test for categorical variables and Mann-Whitney U Test for continuous variables due to small sample size.Abbreviations: IQR, Interquartile Range. Demographics and Clinical Characteristics Stratified by Arrhythmic Presentation. Data are presented as n (%) for categorical variables and Median [Interquartile Range] for continuous variables. Valid percent was used. P-value <0.05 indicates statistical significance. P-values were calculated using Fisher's Exact Test for categorical variables and Mann-Whitney U Test for continuous variables due to small sample size. Abbreviations: IQR, Interquartile Range. Patients with arrhythmic presentation were older than those without arrhythmia, with a median age of 14 years (IQR 1.13–31.50) versus 1 year (IQR 0.25–14.50), respectively (p = 0.044). Although most patients in both groups were pediatric, neither pediatric status nor sex differed between groups. Tuberous sclerosis was absent in the arrhythmic group but present in 43.5% of the non-arrhythmic group (p = 0.014). Clinically, syncope and palpitations were more frequently observed in the arrhythmic group, occurring in 45.5% versus 0% (p = 0.002) and 63.6% versus 21.7% (p = 0.026), respectively. Tumor characteristics Tumor characteristics and multimodality imaging findings are shown in Table 2. Patients with arrhythmic presentation had larger tumors, with a median maximum diameter of 6.80 cm (IQR 5.75–7.35) compared with 2.30 cm (IQR 1.10–3.90) in the non-arrhythmic group (p < 0.001). Tumor diagnosis also differed between groups (p = 0.002). Fibromas were more frequent in the arrhythmic group than in the non-arrhythmic group (45.5% vs. 13.0%), whereas rhabdomyomas were absent in the arrhythmic group and constituted the predominant histology in the non-arrhythmic group (56.5%). Hemangioma/vascular tumors were also more common in the arrhythmic group (36.4% vs. 13.0%). Table 2Tumor Characteristics and Multimodal Imaging Findings Stratified by Arrhythmic Risk.VariableVA\SCD Group (n = 11)Non-Arrhythmic Group (n = 23)P-ValueTumor Diagnosis, n (%)0.002 Fibroma5 (45.5)3 (13) Rhabdomyoma0 (0)13 (56.5) Hemangioma / Vascular4 (36.4)3 (13) Other / Malignant2 (18.2)4 (17.4)Tumor Dimensions, Median [IQR] Max Diameter (cm)6.80 (5.75–7.35)2.30 (1.10–3.90)< 0.001Tumor Count, n (%)0.017 Solitary Mass11 (100)14 (60.9) Multiple Masses0 (0)9 (39.1)Anatomical Location, n (%)0.219 LV8 (72.7)14 (60.9) RV2 (18.2)4 (17.4) Biventricular0 (0)5 (21.7) Pericardial1 (9.1)0 (0)CMR Tissue Characterization⁎, n (%) LGE Positive (Scar)10 (90.9)11 (57.9)0.100 T2 Hyper-intense (Edema)5 (45.5)10 (50)0.621 Hyper-perfusion6 (60)13 (65)0.999CT / Morphological Features, n (%) Calcification Present2 (18.2)1 (4.3)0.239Data are presented as n (%) for categorical variables and Median [Interquartile Range] for continuous variables. Valid percent was used. P-value <0.05 indicates statistical significance. P-values were calculated using Fisher's Exact Test for categorical variables and Mann-Whitney U Test for continuous variables due to small sample size.Abbreviations: CMR, Cardiac Magnetic Resonance; LGE, Late Gadolinium Enhancement; LV, Left Ventricle; RV, Right Ventricle.⁎Percentages for CMR variables are calculated based on the number of patients with interpretable sequences; denominators for the non-arrhythmic group were n = 19 for LGE and n = 20 for T2/Perfusion. Tumor Characteristics and Multimodal Imaging Findings Stratified by Arrhythmic Risk. Data are presented as n (%) for categorical variables and Median [Interquartile Range] for continuous variables. Valid percent was used. P-value <0.05 indicates statistical significance. P-values were calculated using Fisher's Exact Test for categorical variables and Mann-Whitney U Test for continuous variables due to small sample size. Abbreviations: CMR, Cardiac Magnetic Resonance; LGE, Late Gadolinium Enhancement; LV, Left Ventricle; RV, Right Ventricle. Percentages for CMR variables are calculated based on the number of patients with interpretable sequences; denominators for the non-arrhythmic group were n = 19 for LGE and n = 20 for T2/Perfusion. Tumor multiplicity further distinguished between the two groups. All patients with arrhythmic presentation had a solitary ventricular mass, whereas multiple masses were observed only in the non-arrhythmic group (39.1%), yielding a marked difference in tumor count pattern (p = 0.017). By contrast, anatomical distribution did not differ between groups (p = 0.219), with the left ventricle being the most frequent site in both cohorts. Left ventricular masses were present in 72.7% of the arrhythmic group and 60.9% of the non-arrhythmic group, while right ventricular masses occurred in 18.2% and 17.4%, respectively; biventricular involvement was observed only in the non-arrhythmic group. On cardiac magnetic resonance imaging, late gadolinium enhancement was highly prevalent in the arrhythmic group (90.9%) compared with the non-arrhythmic group (57.9%), although this difference did not reach statistical significance (p = 0.100). Similarly, no significant between-group differences were observed in T2 hyperintensity (45.5% vs. 50.0%, p = 0.621), hyper-perfusion (60.0% vs. 65.0%, p = 0.999), or calcification on CT/morphologic assessment (18.2% vs. 4.3%, p = 0.239). Representative CMR features of a ventricular fibroma are shown in Fig. 1. CMR for cardiac fibroma; Steady-state free precession (SSFP) Cine images of the patient (A; 4-chamber view, B; axial view) demonstrating site of fibroma at basal antero-lateral wall in relation to PMVL. Hemodynamic impact Hemodynamic impact and management data are summarized in Table 3. There were no significant differences in ventricular systolic function between groups, with median LVEF of 61% (IQR 55–67) in the arrhythmic group and 63% (IQR 56.5–66.5) in the non-arrhythmic group (p = 0.675), and median RVEF of 65% (IQR 58–68) versus 61% (IQR 57–69.5), respectively (p = 0.552). Likewise, moderate-to-severe valvular disease (27.3% vs. 17.4%, p = 0.656) and outflow tract obstruction (9.1% vs. 17.4%, p = 0.999) were not significantly different between groups. Table 3Hemodynamic Impact.VariableVA\SCD (n = 11)Non-Arrhythmic Group (n = 23)P-ValueVentricular Function LVEF (%), Median [IQR]61 (55–67)63 (56.50–66.50)0.675 RVEF (%), Median [IQR]65 (58–68)61 (57–69.5)0.552Structural Impact, n (%) Mod/Severe Valve Disease3 (27.3)4 (17.4)0.656 Outflow Obstruction (RVOT/LVOT)1 (9.1)4 (17.4)0.999Data are presented as n (%) for categorical variables and Median [Interquartile Range] for continuous variables. Valid percent was used. P-value <0.05 indicates statistical significance. P-values were calculated using Fisher's Exact Test for categorical variables and Mann-Whitney U Test for continuous variables due to small sample size.Abbreviations; IQR, Interquartile Range; LVEF, Left Ventricular Ejection Fraction; RVEF, Right Ventricular Ejection Fraction. Hemodynamic Impact. Data are presented as n (%) for categorical variables and Median [Interquartile Range] for continuous variables. Valid percent was used. P-value <0.05 indicates statistical significance. P-values were calculated using Fisher's Exact Test for categorical variables and Mann-Whitney U Test for continuous variables due to small sample size. Abbreviations; IQR, Interquartile Range; LVEF, Left Ventricular Ejection Fraction; RVEF, Right Ventricular Ejection Fraction. Management strategies Management was individualized. Surgery was recorded in 6 VA/SCD and 9 non-arrhythmic patients, transcatheter embolization/feeding-vessel occlusion in 2, ICD implantation in 2 patients and implantable loop-recorder surveillance in 4 patients. One rhabdomyoma patient underwent accessory-pathway ablation. The non-arrhythmic RV lymphoma patient received 3 systemic chemotherapy regimens. Tumor-specific descriptive analysis and outcomes Fibroma was diagnosed in 8 patients. Five (62.5%) presented with VA/SCD: 4 with sustained VT and 1 with SCD. Median maximum diameter was 5.5 [4.0–7.0] cm in the 5 VA/SCD cases and 4.5 [4.3–4.8] cm in the 3 non-arrhythmic cases. Five patients underwent surgical resection, including 4 of the 5 VA/SCD cases; 2 were awaiting or undergoing evaluation for surgery, and the patient with SCD died before definitive treatment. Representative gross surgical and histopathological findings from a resected fibroma are shown in Fig. 2. Gross and histopathological appearance of resected fibroma. (A, B) Gross specimen. (C) Hematoxylin-eosin and (D) picrosirius-red staining demonstrate dense fibrous tissue. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) No recurrent ventricular arrhythmia was documented in one resected VA/SCD case; however, postoperative rhythm follow-up was incomplete or unavailable in several others, preventing reliable assessment of arrhythmia recurrence after surgery. Rhabdomyoma was diagnosed in 13 patients, all of whom were pediatric; 10 had TSC and 8 had multiple tumors. None presented with or developed sustained VA/SCD during the available follow-up. Four patients underwent resection or debulking for obstruction or other structural indications, whereas 9 were managed conservatively with clinical and imaging surveillance. Serial imaging demonstrated tumor stability or regression when follow-up studies were available, although complete resolution was not consistently documented. One patient underwent accessory-pathway ablation after tumor regression. Hemangioma was diagnosed in 6 patients, of whom 3 presented with sustained VT. Two underwent surgical resection, 2 were managed with surveillance, and 2 patients with complex tumors underwent transcatheter devascularization followed by secondary-prevention ICD implantation. One surgically treated patient died postoperatively. In the 2 devascularized cases, follow-up imaging demonstrated reduced tumor perfusion with regression or stabilization; infrequent recurrent VT was subsequently detected and successfully terminated by ICD antitachycardia pacing. Long-term rhythm outcomes were not uniformly available for the remaining resected or observed cases. One mesothelial-hyperplasia case was recorded. Definitive biopsy or resection could not be completed, the mass persisted on the last available imaging study, and the patient subsequently developed SCD I month post presentation. The remaining rare lesions comprised 2 lipomatous tumors, 2 papillary fibroelastomas, 1 RV lymphoma, and 1 undetermined RV neoplasm. The discrete RV/pericardial lipoma presented with sustained VT and underwent resection with ILR surveillance; no malignant arrhythmia was documented during 1.5 years of follow-up, whereas diffuse lipomatosis was managed conservatively without sustained VA/SCD. Both papillary fibroelastomas were surgically excised, with no sustained VA/SCD documented at last follow-up. The RV lymphoma patient had no sustained VA/SCD and received 3 systemic chemotherapy regimens after biopsy and pericardial procedures; no radiotherapy was documented, and subsequent oncological follow-up occurred elsewhere. The undetermined RV neoplasm progressed with RV distortion and pericardial effusion; despite oncology referral, no definitive biopsy or tumor-directed therapy was recorded before SCD. On viewing VT morphology in 12 lead ECG, it was compatible with tumor location (Table 4), (Fig. 3). Table 4VT morphology, tumor location, and management.Tumor/ageVT morphologyTumor locationRelationManagement/outcomeFibroma, 1.5 yLBBB; late transition; left-superior axisInferior/inferolateral/lateral RV wallCompatibleExcision; rhythm follow-up incompleteFibroma, 45 yRhythm strip onlyMid-anteroseptal LV wallNot assessableResection; follow-up unavailableHemangioma, 6 MRBBB; V4 transition; left-superior axisExtensive interventricular septumCompatibleResection; postoperative deathFibroma, 14 yRBBB; V2 transition; right-inferior axisApical lateral LV wallCompatibleExcision; no recurrence documentedFibroma, 14 yRBBB; V5 transition; left-superior axisBasal-mid lateral LV wallCompatibleExcision and ILR; follow-up incompleteHemangioma, 29 yRBBB; V5 transition; left-superior axisBasal/mid septal and inferior LVCompatibleEmbolization and ICD; later VT treated by ATPHemangioma, 27 yRBBB; left-superior axisLarge lateral LV massCompatibleFeeding-vessel occlusion and ICD; later ATPLipoma, 34 yLBBB; late transition; left-superior axisBasal-mid RV free wall/pericardiumCompatibleExcision and ILR; event-free for 1.5 y VT morphology, tumor location, and management. Twelve‑lead ECG during ventricular tachycardia in a patient with a left-ventricular fibroma. The right bundle-branch-block morphology, late precordial transition, and left-superior axis were anatomically compatible with the tumor location. Discussion In this analysis of patients with ventricular cardiac masses, the main finding is that the phenotype associated with VA/SCD was characterized by larger tumor size, solitary morphology, and histology enriched for fibroma and vascular tumors, whereas conventional indicators of hemodynamic burden such as EF or valvular lesions did not clearly distinguish higher-risk from lower-risk patients. In our cohort, patients with arrhythmic presentation had markedly larger masses than those without arrhythmia and all arrhythmic cases had solitary lesions. Fibroma or vascular tumors predominated in the arrhythmic group, while rhabdomyoma was largely confined to the non-arrhythmic group. By contrast, left and right ventricular systolic function, valvular involvement, and outflow tract obstruction were similar between groups. These findings support the concept that, in ventricular tumors, arrhythmic risk is driven more by the intrinsic electrical substrate created by the mass than by global mechanical compromise alone. Contemporary data emphasize that cardiac tumors may provoke arrhythmia through direct myocardial infiltration, fibrosis or creation of heterogeneous interfaces that favor re-entry, independent of whether the lesion is histologically benign or malignant [7]. Among all variables examined, tumor size emerged as the strongest probable discriminator in our analysis. This is biologically plausible. Larger ventricular masses are more likely to involve a greater volume of myocardium, produce broader zones of anisotropic conduction, and interact more extensively with scarred or remodeled tissue, thereby increasing the likelihood of sustained ventricular arrhythmia. This interpretation is supported by recent pediatric data showing that both tumor type and tumor dimensions can predict ventricular arrhythmias and cardiac death in primary benign cardiac tumors [8], as well as by fibroma-focused series in which larger or more extensive lesions were frequently associated with symptomatic arrhythmia and intervention [9]. The observed relationship between histology and arrhythmic presentation is also consistent with current understanding of tumor biology. Fibromas are composed of dense fibrocollagenous tissue and have long been recognized as one of the most arrhythmogenic primary cardiac tumors, particularly when intramural or septal. Recent reports continue to confirm that fibromas carry a substantial burden of ventricular tachycardia and that surgical resection, when feasible, reduces but may not completely abolish future arrhythmic risk [9], [10]. In contrast, rhabdomyomas often follow a distinct natural history, especially in children and in association with tuberous sclerosis complex (TSC), with many lesions regressing spontaneously over time [11]. Accordingly, the higher prevalence of TSC in the non-arrhythmic group in our study should not be interpreted as a protective effect of TSC itself; rather, it likely reflects the predominance of rhabdomyoma within that subgroup and the different electrophysiologic behavior of this tumor type. Similarly, recent data over cardiac hemangioma emphasize that vascular tumors may behave unpredictably depending on size and location and can produce clinically significant arrhythmias despite benign histology [12]. A particularly interesting finding in our cohort was the association between solitary tumor pattern and arrhythmic presentation. All patients with VA/SCD presentation had a single lesion, whereas multiple tumors were observed only in the non-arrhythmic group. This may again reflect underlying pathology rather than count alone. Multiple tumors in pediatric practice are commonly rhabdomyomas, often linked to TSC, whereas solitary intramural ventricular masses are more likely to represent fibroma or other focal substrates capable of supporting macro-re-entry [10]. Our data therefore suggest that multiplicity should not automatically be equated with higher electrical risk; in ventricular masses, the combination of size, focality, and histology may be more informative than lesion number by itself. The cardiac magnetic resonance findings in this analysis also deserve attention. Although late gadolinium enhancement (LGE) did not reach statistical significance, it was numerically more frequent in the arrhythmic group. Given the limited sample size, this likely represents a signal that the study was underpowered to confirm definitively. In ventricular tumors, LGE may reflect fibrosis, collagen deposition, necrosis, or chronic tissue remodeling, all of which can contribute to an arrhythmogenic substrate [13].The absence of significant differences in T2 hyperintensity or perfusion, alongside the strong size and histology signals, may indicate that chronic structural substrate is more important than transient inflammatory or perfusion-related changes in determining VA/SCD risk in this population. Another clinically important observation is that mechanical severity and electrical severity were not parallel. Patients with arrhythmic presentation did not have worse ventricular function, more frequent severe valve disease, or more outflow tract obstruction. This suggests that the risk of malignant ventricular arrhythmia cannot be inferred simply from preserved or impaired ventricular performance. From a practical standpoint, a patient with a relatively preserved ejection fraction may still carry substantial arrhythmic risk if the ventricular mass is large, solitary, and of an arrhythmogenic histology. This message is important because it argues for risk stratification that integrates tumor phenotype and imaging substrate, not just standard heart failure or obstruction metrics. From a management perspective, our findings support a risk-adapted approach integrating tumor phenotype and arrhythmic presentation. Patients with large, solitary, and arrhythmogenic tumors may benefit from early surgical resection, even in the absence of significant hemodynamic compromise, although residual arrhythmic risk may persist post-operatively. In patients undergoing interventions for arrhythmogenic tumors, surveillance of arrhythmia recurrence especially using ILR can be a good strategy to guide further management. Conversely, low-risk lesions such as small or multiple rhabdomyomas may be managed conservatively with serial imaging and surveillance. Advanced imaging, especially CMR, may further refine risk stratification by identifying arrhythmogenic substrate. Overall, management should be individualized, combining tumor characteristics, imaging findings, and clinical presentation. These data should be interpreted cautiously because our analysis was exploratory and based on a relatively small single-center cohort. The limited number of events restricts formal multivariable modeling and raises the possibility that some observed associations are partially driven by clustering of specific tumor types. Twenty-four patients were pediatric and only 10 were adults; adult metastatic and primary malignant tumors were underrepresented, limiting adult generalizability. Symptoms such as palpitations or unwitnessed syncope may have been under-recorded in infants. Tissue confirmation, imaging sequences, treatment details, and longitudinal rhythm monitoring were not uniform, and some patients were lost to follow-up or treated elsewhere. Nonetheless, the coherence of the size, morphology, histology, and imaging signals supports their relevance as candidate markers for future risk stratification studies. Conclusion This ventricular-mass analysis indicates that arrhythmic risk is not uniform across cardiac tumors. Rather, it appears to cluster in a recognizable phenotype defined by greater size, solitary growth pattern, and arrhythmogenic histology, with a possible contribution from scar-like substrate on CMR. Future multicenter studies are needed to validate these findings and to determine whether these features can be incorporated into a practical algorithm for rhythm surveillance, surgical timing, and device-based prevention of sudden cardiac death. CRediT authorship contribution statement Mohamed S. Riad: Writing – original draft, Methodology, Conceptualization. Mohamed M. Abdelfadil: Writing – original draft, Methodology. Mostafa Wanees Ahmed El Husseny: Investigation, Data curation. Taha Abd-ElSalam Ashraf Taha: Formal analysis, Data curation. Eslam Ahmed: Visualization, Investigation. Mahmoud Shaaban: Investigation, Data curation. Ayman M. Ibrahim: Validation, Conceptualization. Ahmed Elguindy: Project administration. Hesham Bahaa: Investigation. Hatem Hosny: Investigation. Ahmed Afifi: Investigation. Omnia Kamel: Writing – review & editing, Supervision, Project administration, Conceptualization. Funding The authors declare that no fund was received for this research. Declaration of competing interest The authors declare that there is no conflict of interest related to this article. Contributor Information Mohamed S. Riad, Email: Mohamed.s.riad@gmail.com. Mohamed M. Abdelfadil, Email: Mmm37@fayoum.edu.eg. Mostafa Wanees Ahmed El Husseny, Email: dr.mostafawanees@gmail.com. Taha Abd-ElSalam Ashraf Taha, Email: Ta1295@fayoum.edu.eg. Eslam Ahmed, Email: Eslamahmed2425@gmail.com. Mahmoud Shaaban, Email: mahmoud.shaban@med.tanta.edu.eg. Ayman M. Ibrahim, Email: a.m.ibrahim@surrey.ac.uk. Ahmed Elguindy, Email: ahmed.elguindy@myf-egypt.org. Hesham Bahaa, Email: hesham.bahaa@gmail.com. Hatem Hosny, Email: hatem.hosny@myf-egypt.org. Ahmed Afifi, Email: ahmed.afifi@myf-egypt.org. Omnia Kamel, Email: omnia.kamel@myf-egypt.org. References